CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of 8,966,077 shares of common stock, equal to 5.29% as of 12/31/2025.
The filing states the holders have shared voting and shared dispositive power over those 8,966,077 shares and lists Delaware and United States citizenships for the reporting entities and person.
Positive
None.
Negative
None.
Insights
Large passive stake reported: 5.29% ownership reported as of 12/31/2025.
The filing shows 8,966,077 shares are beneficially owned collectively by Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang, with shared voting and dispositive power. The filing is a Schedule 13G-style passive ownership disclosure.
Because the report lists shared power rather than sole control, the stake appears nondispositive by a single holder; material impact on control is not evident from the excerpt. Subsequent filings or proxy disclosures would clarify any change in intent or voting behavior.
What stake does Kynam Capital report in CytomX (CTMX)?
Kynam Capital reports beneficial ownership of 8,966,077 shares, equal to 5.29%. The Schedule 13G lists this position as of 12/31/2025, with shared voting and dispositive power among the reporting entities and individual.
Who are the filers on the Schedule 13G for CTMX?
The filers are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. The filing gives Delaware citizenship for the first two and United States citizenship for Yue Tang, and an address in Princeton, New Jersey.
Does the Schedule 13G indicate sole voting control over the shares?
No. The filing shows 0 shares of sole voting power and reports 8,966,077 shares of shared voting power. It therefore attributes voting and dispositive authority to the group rather than to a single filer.
What date is the ownership percentage based on in the filing?
The reported ownership—8,966,077 shares or 5.29%—is stated as of 12/31/2025. Signatures on the filing are dated 03/04/2026.
Does this Schedule 13G indicate that CytomX insiders sold or purchased shares?
No. The document is a beneficial ownership report showing a passive stake; it does not describe purchases or sales. It lists beneficial ownership and voting/dispositive power as of 12/31/2025.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CytomX Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Kynam Capital Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
8,966,077.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
8,966,077.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,966,077.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.29 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Kynam Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
8,966,077.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
8,966,077.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,966,077.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.29 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Yue Tang
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
8,966,077.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
8,966,077.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,966,077.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.29 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CytomX Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CALIFORNIA
94080
Item 2.
(a)
Name of person filing:
Kynam Capital Management, LP
Kynam Capital Management GP, LLC
Yue Tang
(b)
Address or principal business office or, if none, residence:
221 ELM ROAD
PRINCETON, New Jersey
08540
(c)
Citizenship:
Kynam Capital Management, LP - DELAWARE
Kynam Capital Management GP, LLC - DELAWARE
Yue Tang - UNITED STATES
(d)
Title of class of securities:
Common Stock, $0.00001 par value per share
(e)
CUSIP No.:
23284F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
8,966,077
(b)
Percent of class:
5.29 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(ii) Shared power to vote or to direct the vote:
Kynam Capital Management, LP - 8,966,077
Kynam Capital Management GP, LLC - 8,966,077
Yue Tang - 8,966,077
(iii) Sole power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(iv) Shared power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 8,966,077
Kynam Capital Management GP, LLC - 8,966,077
Yue Tang - 8,966,077
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
